tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Chris Schott, 7 are a SELL (4.05%), 41 are a HOLD (23.7%), 125 are a BUY (72.25%).
Analyst Chris Schott, currently employed at JPMORGAN, carries an average stock price target met ratio of 42.46% that have a potential upside of 19.7% achieved within 249 days.
Chris Schott’s has documented 360 price targets and ratings displayed on 28 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ABBV, AbbVie at 13-Nov-2024.
Analyst best performing recommendations are on EQRX (EQRX).
The best stock recommendation documented was for EQRX (EQRX) at 8/16/2022. The price target of $5.5 was fulfilled within 3 days with a profit of $0.67 (13.87%) receiving and performance score of 46.24.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$205
$39.27 (23.70%)
2 days ago
(15-Nov-2024)
2/3 (66.67%)
$39.27 (23.70%)
507
Buy
$200
$34.27 (20.68%)
$190
4 days ago
(13-Nov-2024)
12/13 (92.31%)
$28.57 (16.67%)
490
Buy
$215
$49.27 (29.73%)
$226
5 days ago
(12-Nov-2024)
8/10 (80%)
$39.86 (22.76%)
293
Buy
$224
$58.27 (35.16%)
$231
5 days ago
(12-Nov-2024)
12/15 (80%)
$48.86 (27.90%)
488
Buy
$221
$55.27 (33.35%)
$171
11 days ago
(06-Nov-2024)
22/23 (95.65%)
$18.37 (9.07%)
427
Which stock is Chris Schott is most bullish on?
Which stock is Chris Schott is most reserved on?
What Year was the first public recommendation made by Chris Schott?
